Genentech, a member of Roche (RHHBY), announced that the FDA has approved the combination regimen of venclexta plus acalabrutinib for the treatment of previously untreated adults with chronic lymphocytic leukemia, based on results from the Phase III AMPLIFY study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Roche price target raised to CHF 340 from CHF 320 at Berenberg
- Roche management to meet virtually with Piper Sandler
- VYMI vs. VIGI vs. VPU: Which Vanguard Dividend ETF Is Best for Steady Passive Income?
- FDA to begin requiring on clinical trial
- FDA to begin requiring one clinical trial in drug approvals